#USA #AI Solutions #Berkeley Heights #Axtria #Pharma

Axtria's Prestigious Recognition

Axtria, a pioneer in AI-driven data analytics for the life sciences sector, has been awarded Frost & Sullivan's 2025 Global Company of the Year in the pharma commercial solutions arena. This accolade represents the highest level of recognition from the renowned market research firm, solidifying Axtria's position as a leader in pharmaceutical commercialization. This recognition builds upon Axtria's previous acknowledgment as the leader in Frost & Sullivan's inaugural Pharmaceutical Commercialization Solutions and Services Industry Radar Report in December 2024.

A Commitment to Innovation

Frost & Sullivan employs a detailed evaluation framework that assesses Visionary Innovation & Performance and Customer Impact to determine the top contenders. Axtria has excelled in various areas, including leadership focus, the implementation of best practices, notable financial results, and strong brand equity. Aarti Chitale, Industry Principal at Frost & Sullivan, stated, "Axtria enables real-time, insight-driven decision-making that helps biopharma companies enhance launch strategies, remain agile, and improve profitability." This reflects Axtria's commitment to providing data ecosystems that integrate seamlessly with client systems, while delivering predictive analytics that boost engagement with healthcare professionals and patients alike.

Future-Proofing Pharmaceutical Commercialization

The global market for pharma commercial solutions is anticipated to exceed $200 billion by 2030, with an annual growth rate of 7-8%. This growth is fueled by the shift towards precision medicine and omnichannel engagement. Foreseeing this transition, Axtria has crafted an integrated ecosystem that encompasses machine learning and AI technologies, which empower organizations to make autonomous, real-time decisions. The results have been noteworthy,

• - Up to 40% reduction in data infrastructure costs
• - 60% faster sales alignment workflows
• - 35-40% savings on AI implementation costs
• - 15% increase in prescriptions from targeted healthcare providers
• - Marketing analysis timelines reduced from months to mere weeks.

Exemplifying Performance

The performance of Axtria speaks volumes about its impact. For instance, during the pandemic, a leading biopharma company successfully launched a treatment for schizophrenia and bipolar depression by leveraging Axtria's capabilities. This included unifying fragmented datasets and automating multi-channel executions, which led to significant engagement and growth within just eleven months:

• - 21% overall prescription boost
• - 20-25% surge in healthcare practitioner engagement
• - 50-60% field team adoption rate.

Furthermore, as highlighted by Marcos Ainchil, BPR Analyst at Frost & Sullivan, Axtria is seen prioritizing proof of impact over aggressive discounting, a strategic decision that differentiates them from other competitors that opt to undercut prices.

A Vision for the Future

Axtria's leadership in agentic AI has been further established with the launch of SalesIQ—a comprehensive evolution of its sales planning platform. This platform not only accelerates intelligent decision-making but also exemplifies Axtria's ongoing commitment to fostering intelligent commercialization. Last September, they announced a substantial $240 million investment and a share buy-back program with Kedaara Capital, marking one of the most significant liquidity events focused on employees in the industry. Axtria boasts over two decades of expertise in commercialization, with teams spread across the United States, Europe, Canada, Japan, and India, allowing them to continuously focus on measurable outcomes.

About Axtria

Founded with the mission of enhancing patient outcomes through improved data science and software applications, Axtria stands as a reputable global authority in providing cloud-based software and data analytics for the life sciences. Their ongoing commitment to innovation helps pharmaceutical, medical device, and diagnostics companies optimize their value chain, transitioning effectively from data to insights and ultimately to actionable strategies. As a participant in the United Nations Global Compact, Axtria is also dedication to human rights, labor, environmental sustainability, and anti-corruption initiatives.

For more information about their products and solutions, visit www.axtria.com.